ClinicalTrials.gg
CompletedNCT01259531STRONGUpdated Mar 30, 2012

Study of a α1A Adrenoceptor Selective Antagonist Silodosin to Treat Severe Benign Prostatic Hyperplasia(BPH)

A Phase 4 interventional study of Silodosin in Benign Prostatic Hyperplasia, sponsored by JW Pharmaceutical. Completed at 1 site in Korea, Republic of. Open to male participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2012-03-30.

Sponsored by JW Pharmaceutical · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
100
Allocation
Not applicable
Ages
50 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 19 studies testing silodosin in Prostatic Hyperplasia — 4 open to participants now, 4 under way, none of them phase 3. silodosin · Prostatic Hyperplasia.

Enrollment
16th of 19
100 · median 141
Started
2010
with 1 other
Phase 4
11 of 19
4 open now
Registered
8th of 19
by date
Lead sponsor
3 of 19
JW Pharmaceutical

Among the 19 studies testing silodosin in Prostatic Hyperplasia, this one is the 16th largest by enrollment, is one of 2 that started in 2010, is one of 11 in phase 4, and was the 8th registered.

Prostatic Hyperplasia

828 studies on the registry are indexed under Prostatic Hyperplasia; 179 are open to participants now.

Browse Prostatic Hyperplasia studies →

Open to participants now

4 of the 19 studies testing silodosin in Prostatic Hyperplasia are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About silodosin

silodosin: first FDA approval 2008 (RAPAFLO), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 102 Prostatic Hyperplasia studies recruiting now, 70 (69%) set no upper age limit and 4 (4%) stop at 75 or younger; 7 take children under 18; 7 take healthy volunteers.

This study: 50 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies testing silodosin in Prostatic Hyperplasia, or all of them as a file.
02

Study summary

This clinical study is designed to evaluate the efficacy and safety of silodosin in a 12 week treatment of patients with severe urinary disorders associated with benign prostatic hyperplasia (BPH).

03

Conditions studied

  • Benign Prostatic Hyperplasia

Browse trials for

Keywords

  • strong
  • silodosin
  • benign prostatic hyperplasia
  • BPH
  • lower urinary tract symptoms associated with severe BPH
04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Is at least 50 years old
  • Has a urinary disturbance associated with severe BPH and has a total IPSS score 20 or higher
  • Has a QoL score of 3 or higher
  • Has a urine volume of 120mL or greater and a Qmax of below 15mL/sec
  • Has a PRV of below 100mL
  • Voluntarily decides to participate in this trial and sign with form

Exclusion criteria

Exclusion Criteria:

  • Has been administered silodosin
  • Has been administered an α1A-adrenoceptor blocker within one month
  • Has been prescribed antiandrogens except 5α-reductase inhibitors within a year
  • Has had phytotherapy within 3 months
  • Has had prostatectomy
  • Has had intrapelvic radiation therapy
  • Has had transurethral microwave hyperthermia of transurethral needle ablation
  • Is suspected to have implications that are likely to affect urine passing such as neurogenic bladder, bladder calculus or active urinary tract infection (UTI).
  • Is conducting self-catherterization
  • Has a renal impairment with a serum creatinine of 2.0mg/dL or greater
  • Has severe hepatic disorders (hepatic insufficiency, cirrhosis, jaundice, hepatoma) or has a total of 2.5mg/dl or higher or has /ALT 2.5 times higher than the normal (upper) level
  • Has suffered from a severe arrhythmia, cardiac failure, cardiac infarction, unstable angina, cerebral infarction within 6 months
  • Has experienced allergy to α1 receptor blockers
  • Has orthostatic hypotension around the time of Screening Visit
  • Has participated in other clinical trials within 8 weeks prior to Screening Visit
  • Has a Prostate specific antigen(PSA) of higher 10ng/mL or has been diagnosed with tumor identified by a even though he has a PSA of lower 10ng/mL (Patient who has been administered 5α-reductase inhibitors for more than 3 months are presumed to have 2 times higher than their actual PSA levels)
  • Has been taking unstable dosing of 5α-reductase inhibitors like finasteride or dutasteride for the past 3 months or is expected to change the dosage during the trial.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
100 participants (actual)

Study arms

  • Experimental
    Silodosin

    Silodosin will be administered during 12 weeks, 8 mg (4 mg x 2 cap) QD with morning meal.

    Drug: Silodosin

Interventions

  • Silodosin will be administered during 12 weeks, 8 mg (4 mg x 2 cap) QD with morning meal.

    Also known as: Brand name in Korea : THRUPAS

06

What researchers measure

Primary outcomes

  1. Total International prostate symptom score(IPSS) score before and after treatment

    Assess the improvement of lower urinary tract symptoms with change in total IPSS score before and after treatment.

    Time frame: For 12 weeks

Secondary outcomes

  1. Quality of life(QoL) score before and after treatment

    Assess the improvement of lower urinary tract symptoms with change in QoL score before and after treatment.

    Time frame: For 12 weeks

  2. Maximal urinary flow rate(Qmax) before and after treatment

    Assess the improvement of lower urinary tract symptoms with change in Qmax before and after treatment.

    Time frame: For 12 weeks

  3. Voiding score of IPSS before and after treatment

    Assess the improvement of lower urinary tract symptoms with change in voiding scores before and after treatment.

    Time frame: For 12 weeks

  4. Storage scores of IPSS before and after treatment

    Assess the improvement of lower urinary tract symptoms with change in storage scores before and after treatment.

    Time frame: For 12 weeks

  5. Post void residual urine volume(PVR) before and after treatment

    Assess the improvement of lower urinary tract symptoms with change in post void residual urine volume(PRV) before and after treatment.

    Time frame: For 12 weeks

07

Study locations

1 site
  • Seoul national university hospital
    Seoul, Korea, Republic of
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2010, a primary completion of Sep 2011 and a completion of Sep 2011. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 7, 2010
First posted
Dec 14, 2010
Start
Dec 2010
Primary completionActual
Sep 2011
CompletionActual
Sep 2011
Last update
Mar 30, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 30, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01259531
Lead sponsor
JW Pharmaceutical
Collaborators
Chonnam National University Hospital, Kangdong Sacred Heart Hospital, Yeungnam University Hospital, Pusan National University Hospital, Seoul National University Hospital, Samsung Medical Center, Seoul St. Mary's Hospital, Korea University Guro Hospital, Chonbuk National University Hospital, Asan Medical Center
Responsible party
Sponsor
First posted
Dec 14, 2010
Start date
Dec 2010
Primary completion
Sep 2011
Completion
Sep 2011
Last update
Mar 30, 2012

Study contacts

G.S. Park, Prof
study chair · Chonnam National Univ.
D.Y. Yang, Prof
principal investigator · Kangdong Sacred Heart
K.H. Moon, Prof
principal investigator · Yeongnam Univ. Medical
N.C. Park
principal investigator · Pusan National Univ. Hospital
S.W. Kim, Prof
principal investigator · Seoul National Univ. Hospital
S.W. Lee, Prof
principal investigator · Samsung Medical Center
S.W. Kim, Prof
principal investigator · Seoul St. Mary's Hospital
D.G. Moon, Prof
principal investigator · Korea Univ. Guro Hospital
J.K. Park, Prof
principal investigator · Chunbuk National Univ. Hospital
T.Y. Ahn, Prof
principal investigator · Asan Medical Center

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Silodosin

Start the discussion